Remove 2019 Remove Leads Remove Safety
article thumbnail

New Parkinson’s drug formulation “nearly doubles” exposure

European Pharmaceutical Review

Therefore “This could improve the overall safety and tolerability of risvodetinib.” “… compared to the capsules currently in use in the 201 clinical trial, the smaller tablets may overcome challenges patients have swallowing oral medication as a result of their disease.

Safety 98
article thumbnail

Navigating the regulatory challenge of PFAS for pharmaceutical manufacturers

European Pharmaceutical Review

This article explores the potential impact of the proposal and considers how manufacturers can ensure the safety and reliability of their products. This may cover anything from waste management, decontamination and health and safety issues to project controls including scheduling, resource tracking and communications.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Could acoziborole eliminate sleeping sickness in Africa?

European Pharmaceutical Review

Between 2016 and 2019, DNDi and its partners led an open-label, Phase II/III study to assess the safety and efficacy of acoziborole in patients with early- and late-stage g-HAT. The study demonstrated acoziborole has a favourable safety profile, with no significant drug-related safety signals reported.

Safety 98
article thumbnail

Ipsen’s rare disease drug palovarotene knocked back in EU

pharmaphorum

Palovarotene was acquired by Ipsen as part of its $1 billion upfront acquisition of Clementia Pharma in 2019, but almost immediately ran into trouble. It failed a futility test in a pivotal trial and was also placed under a partial clinical hold by the FDA in 2020 while a safety signal was investigated.

FDA 98
article thumbnail

Novel anti-epileptic drug demonstrates efficacy

European Pharmaceutical Review

A new approach to potassium-channel openers for epilepsy Critically, XEN1101 combines the effectiveness of potassium-channel openers with the safety of more traditional drugs, stated study lead author and neurologist Dr Jacqueline French. It ran between January 2019 and September 2021.

article thumbnail

After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome

pharmaphorum

Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some comfort from a mid-stage trial of its candidate for short bowel syndrome (SBS), although its share price remains under pressure. Some children are born with an abnormally short small intestine.

Leads 98
article thumbnail

Dual cystic fibrosis modulator therapy shows efficacy in four-year study

European Pharmaceutical Review

The combination modulator therapy tezacaftor (TEZ) and ivacaftor (IVA) for cystic fibrosis (CF) has demonstrated long-term safety and clinical benefit in a four-year trial. While this clinical trial was still being conducted, a three-part regimen composed of TEZ/IVA plus elexacaftor (Trikafta) was approved in 2019.